These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 17573291

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?
    Junquera L, Gallego L.
    J Oral Maxillofac Surg; 2008 Jul; 66(7):1516-7. PubMed ID: 18571043
    [No Abstract] [Full Text] [Related]

  • 23. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB.
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [Abstract] [Full Text] [Related]

  • 24. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER, Basile JD.
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [Abstract] [Full Text] [Related]

  • 25. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS, Fayans EP.
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [Abstract] [Full Text] [Related]

  • 26. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A, Kressley A, Saif MW.
    JOP; 2009 Mar 09; 10(2):212-4. PubMed ID: 19287122
    [No Abstract] [Full Text] [Related]

  • 27. [Biphosphonates and osteonecrosis].
    Irani J.
    Prog Urol; 2006 Nov 09; 16(5):602. PubMed ID: 17175960
    [No Abstract] [Full Text] [Related]

  • 28. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.
    Oncologist; 2008 Aug 09; 13(8):911-20. PubMed ID: 18695259
    [Abstract] [Full Text] [Related]

  • 29. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 09; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 30. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition.
    Colella G, Campisi G, Fusco V.
    J Oral Maxillofac Surg; 2009 Dec 09; 67(12):2698-9. PubMed ID: 19925998
    [No Abstract] [Full Text] [Related]

  • 31. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation.
    Stübinger S, Dissmann JP, Pinho NC, Saldamli B, Seitz O, Sader R.
    Lasers Surg Med; 2009 Jan 09; 41(1):26-30. PubMed ID: 19143020
    [Abstract] [Full Text] [Related]

  • 32. Management of bisphosphonate-induced osteonecrosis of the jaw.
    Schilling J.
    Northwest Dent; 2008 Jan 09; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
    [Abstract] [Full Text] [Related]

  • 33. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.
    Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL.
    J Oral Maxillofac Surg; 2009 Sep 09; 67(9):1904-13. PubMed ID: 19686928
    [Abstract] [Full Text] [Related]

  • 34. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K.
    Expert Rev Anticancer Ther; 2009 Aug 09; 9(8):1125-34. PubMed ID: 19671032
    [Abstract] [Full Text] [Related]

  • 35. Bisphosphonate related osteonecrosis of the jaw--manifestation in a microvascular iliac bone flap.
    Pautke C, Otto S, Reu S, Kolk A, Ehrenfeld M, Stürzenbaum S, Wolff KD.
    Oral Oncol; 2011 May 09; 47(5):425-9. PubMed ID: 21478047
    [Abstract] [Full Text] [Related]

  • 36. The benefits and costs of bisphosphonates.
    Coleman RE.
    J Support Oncol; 2007 May 09; 5(10):483-4. PubMed ID: 18240670
    [No Abstract] [Full Text] [Related]

  • 37. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA.
    Cancer; 2009 Apr 15; 115(8):1631-7. PubMed ID: 19156913
    [Abstract] [Full Text] [Related]

  • 38. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.
    Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC.
    Am J Otolaryngol; 2009 Apr 15; 30(6):390-5. PubMed ID: 19880027
    [Abstract] [Full Text] [Related]

  • 39. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.
    Tirelli G, Biasotto M, Chiandussi S, Dore F, De Nardi E, Di Lenarda R.
    Head Neck; 2009 Sep 15; 31(9):1249-54. PubMed ID: 19260132
    [Abstract] [Full Text] [Related]

  • 40. [Prevention and therapy of bisphosphonate-induced mandibular osteonecrosis].
    Magyar Onkológia SzerkesztőségeOrszágos Onkológiai Intézet 1122 Budapest Ráth György u. 7-9..
    Magy Onkol; 2009 Dec 15; 53(4):408-9. PubMed ID: 20071315
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.